Please login to the form below

Not currently logged in
Email:
Password:

DiCE Molecules adds Dr Richard Scheller to its board of directors

He currently serves as chief scientific officer at 23andMe

DiCE Molecules Dr Richard SchellerSan Francisco-based DiCE Molecules has appointed Dr Richard Scheller to its board of directors.

Dr Scheller brings nearly 20 years of leadership in drug discovery research and development to DiCE Molecules, and currently serves as chief scientific officer and head of therapeutics at 23andMe.

Prior to this, Dr Scheller spent 14 years at Roche's Genentech, the US biotechnology corporation, where he held a number of R&D roles including executive vice president of research and early development.

Between 1982 and 2001, Dr Scheller was a professor in Stanford University's department of biological sciences, and the department of molecular and cellular physiology.

Since 2004, he has served as an adjunct professor in the department of biochemistry and biophysics at the University of California, San Francisco.

Kevin Judice, president and chief executive of DiCE, said: “I have known Richard for years and had the opportunity to work with him early in my career at Genentech – he is truly a visionary and a distinguished leader in oncology, neuroscience, immunology and infectious disease drug development.

“I am delighted to have the opportunity to work with him again as a member of our board and we look forward to his guidance and leadership as we further prove out our science and bring potential drug targets into the clinic.”

7th June 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics